MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that on November 6, 2024, the Company entered into a new $30 million credit facility with Avenue Venture Opportunities Fund, L.P., a fund of Avenue Capital Group. Proceeds from the facility are intended for general corporate purposes, capital expenditures, wo ...

Core Insights - Ocugen, Inc. is hosting a Clinical Showcase on November 12, 2024, to present updates on its ongoing gene therapy trials for various retinal diseases [1][2] - The event will feature updates on the Phase 3 liMeliGhT clinical trial for retinitis pigmentosa, preliminary data from the Phase 1/2 OCU410 ArMaDa trial for geographic atrophy, and progress from the Phase 1/2 OCU410ST GARDian study for Stargardt disease [2][3] - Ocugen plans to initiate the Phase I clinical trial for its biologic candidate OCU200 for diabetic macular edema within the current quarter [2] Event Details - The Clinical Showcase will take place at the Nasdaq MarketSite in Times Square, New York City, from 10 a.m. to noon ET [1] - Presenters will include key executives and study investigators, providing insights into the clinical trials and patient experiences [3] Company Overview - Ocugen, Inc. focuses on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines aimed at improving health and addressing unmet medical needs [5] - The company is advancing research in multiple areas, including retinal diseases and infectious diseases, leveraging its breakthrough modifier gene therapy platform [5]

Determined the high dose of OCU410ST to be the maximum tolerated doseNo serious adverse events have been reportedApproved proceeding to Phase 2 using high and medium doses of OCU410ST MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian c ...

Core Viewpoint - Ocugen, Inc. is set to host a conference call and live webcast on November 8, 2024, to discuss its third quarter 2024 financial results and provide a business update [1][2]. Company Overview - Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines aimed at improving health and offering hope to patients globally [3]. - The company is advancing a breakthrough modifier gene therapy platform that has the potential to treat multiple retinal diseases with a single product, alongside research in infectious and orthopedic diseases to address unmet medical needs [3]. Conference Call Details - The pre-market earnings announcement will coincide with the conference call on November 8, 2024 [2]. - Dial-in numbers for the call are (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers, with a Conference ID of 9923172 [2]. - A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site [2].

Core Viewpoint - Ocugen, Inc. has announced the lifting of the clinical hold by the FDA on its investigational new drug application for OCU200, a treatment for diabetic macular edema (DME) [1] Company Overview - Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines [5] - The company aims to improve health and offer hope for patients globally through innovative scientific approaches [5] Clinical Trial Details - The Phase 1 clinical trial for OCU200 is designed to treat patients with DME, targeting the underlying disease mechanisms through the integrin pathway [2][3] - The trial will be a multicenter, open-label, dose-ranging study with three cohorts assessing the safety of OCU200, and a fourth cohort combining OCU200 with anti-VEGF therapy [3] Disease Context - DME is a common vision-threatening disease affecting approximately 746,000 people in the United States, characterized by blurriness and progressive vision loss [4] - The prevalence of DME is increasing due to the rising number of diabetes cases in the U.S., making it crucial to address this condition [3] Future Indications - Ocugen intends to explore additional indications for OCU200, potentially treating diabetic retinopathy and wet age-related macular degeneration, which together affect nearly nine million Americans [4]

Core Insights - Ocugen, Inc. is set to present at the 2024 Cell & Gene Meeting on the Mesa, highlighting its focus on gene and cell therapies, as well as vaccines [1][2] - Dr. Shankar Musunuri will discuss Ocugen's modifier gene therapy platform and ongoing clinical trials for retinal diseases, including OCU400, OCU410, and OCU410ST [2][4] - The company aims for BLA and MAA approval for OCU400 by 2026, with the Phase 3 trial currently in progress [2] Company Overview - Ocugen, Inc. is a biotechnology firm dedicated to developing innovative gene and cell therapies and vaccines to improve global health [4] - The company emphasizes its commitment to addressing unmet medical needs in retinal diseases and infectious diseases [4] Event Details - The presentation by Dr. Musunuri is scheduled for October 7, 2024, at 1:30 p.m. MST at the Arizona Biltmore [3] - Virtual attendance options are available for the presentation and other conference sessions [3]

MALVERN, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Arun Upadhyay, Chief Scientific Officer, Head of Research & Development, will participate in an in-person fireside chat moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst, at Chardan's 8th Annual Genetic Medicines Conference being held Septembe ...

Jonathan Storey Source: Corporate Presentation. August 2024. Ocugen Inc. (NASDAQ:OCGN) is a clinical-stage biotechnology company developing gene and cell therapies using its proprietary platforms. They aim to restore retinal function in various ocular diseases. Since I last covered OCGN, the company has made promising strides targeting conditions such as retinitis pigmentosa [RP], goographic atrophy related to dry age-related macular degeneration [dAMD], Stargardt disease, and wet AMD. It also has an intrig ...

Core Insights - Ocugen, Inc. is participating in a workshop titled "U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks" from September 9-11, 2024, in New Delhi, India, with Dr. Shankar Musunuri representing the company [1][2] - The workshop aims to explore opportunities for U.S.-India biotechnology collaboration, aligning with the initiative on Critical and Emerging Technology (iCET) [2] - Ocugen has established a site in Hyderabad, India, to enhance collaboration in the biotechnology sector [2] Company Overview - Ocugen, Inc. focuses on discovering, developing, and commercializing novel gene and cell therapies, and vaccines aimed at improving global health [3] - The company is advancing a breakthrough modifier gene therapy platform that has the potential to treat multiple retinal diseases with a single product [3] - Ocugen is also conducting research in infectious diseases and orthopedic diseases to address unmet medical needs [3]

Core Insights - Ocugen, Inc. is participating in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York, NY, where Dr. Shankar Musunuri will engage in a fireside chat [1][2] - The conference serves as a platform for Ocugen to showcase its recent corporate achievements and future milestones, with one-on-one meetings planned for investors [2] Event Details - The fireside chat is scheduled for September 9, 2024, at 1:30 p.m. ET, located at the Lotte New York Palace Hotel [3] - A live video webcast of the presentation will be available on Ocugen's investor site, with a replay archived for 90 days [3] Company Overview - Ocugen, Inc. focuses on discovering, developing, and commercializing novel gene and cell therapies, and vaccines aimed at improving global health [4] - The company is advancing a unique modifier gene therapy platform that has the potential to treat multiple retinal diseases with a single product, alongside research in infectious and orthopedic diseases [4]